KK POLA ORBIS HOLDINGS header image

KK POLA ORBIS HOLDINGS

4927

Equity

ISIN JP3855900001 / Valor 11993070

Tokyo Stock Exchange (2024-11-21)
JPY 1,362.50-0.76%

KK POLA ORBIS HOLDINGS
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

KK POLA ORBIS HOLDINGS is a Japanese company primarily engaged in the manufacture and sale of cosmetics and skincare products.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (07.08.2024):

Revenue Decline

KK POLA ORBIS HOLDINGS reported revenue of JP¥41.9 billion for the second quarter of 2024, marking a 4.1% decrease from the same period in 2023. This decline in revenue was a significant factor affecting the company's overall financial performance for the quarter.

Net Income Drop

The net income for KK POLA ORBIS HOLDINGS in the second quarter of 2024 was JP¥3.75 billion, which represents a 20% decrease compared to the second quarter of 2023. This reduction in net income highlights the challenges the company faced during this period.

Profit Margin Reduction

KK POLA ORBIS HOLDINGS saw its profit margin decrease to 8.9% in the second quarter of 2024, down from 11% in the same quarter of the previous year. The lower revenue was a primary driver behind this reduction in profit margin.

Earnings Per Share (EPS)

The earnings per share (EPS) for KK POLA ORBIS HOLDINGS in the second quarter of 2024 was JP¥16.95, down from JP¥21.07 in the second quarter of 2023. Despite the decline, the EPS exceeded analyst estimates by 42%, indicating better-than-expected profitability on a per-share basis.

Future Revenue Forecast

Looking ahead, KK POLA ORBIS HOLDINGS's revenue is forecast to grow at an average annual rate of 3.8% over the next three years. This growth rate is slightly below the 4.0% forecast for the Personal Products industry in Japan, suggesting a modest outlook for the company's future revenue performance.

Summarized from source with an LLMView Source

Key figures

-11.2%1Y
-37.4%3Y
-47.1%5Y

Performance

25.0%1Y
27.3%3Y
29.5%5Y

Volatility

Market cap

2021 M

Market cap (USD)

Daily traded volume (Shares)

546,000

Daily traded volume (Shares)

1 day high/low

1377.5 / 1351.5

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

CorVel Corp
CorVel Corp CorVel Corp Valor: 921843
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.40%USD 360.19
LivaNova PLC
LivaNova PLC LivaNova PLC Valor: 28726218
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.30%USD 51.70
Almirall SA
Almirall SA Almirall SA Valor: 3180354
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.12%EUR 8.29
Pharma Mar SA
Pharma Mar SA Pharma Mar SA Valor: 56130572
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.95%EUR 73.10
Faes Farma SA
Faes Farma SA Faes Farma SA Valor: 2837976
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.72%EUR 3.44
Patterson Companies Inc
Patterson Companies Inc Patterson Companies Inc Valor: 1896660
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.10%USD 20.28
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc Xenon Pharmaceuticals Inc Valor: 25419823
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.17%USD 39.80
InMode Ltd.
InMode Ltd. InMode Ltd. Valor: 49023508
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.34%USD 18.48
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc Harmony Biosciences Holdings Inc Valor: 56295735
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.34%USD 33.23
Revance Therapeutics Inc
Revance Therapeutics Inc Revance Therapeutics Inc Valor: 23239569
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.05%USD 3.84